Biotest Pharmaceuticals Announces First Commercial Sales of BIVIGAM™

     Biotest Pharmaceuticals Announces First Commercial Sales of BIVIGAM™

PR Newswire

BOCA RATON, Fla. and DREIEICH, Germany, Feb. 4, 2013

BOCA RATON, Fla. and DREIEICH, Germany, Feb.4, 2013 /PRNewswire/ --Biotest
Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest
AG, is pleased to announce the first commercial sales and successful shipments
of BIVIGAM™ [Immune Globulin Intravenous (Human), 10% Liquid] into the
pharmaceutical distribution channel for use by physicians, pharmacists and
hospitals throughout the United States. The product is now available on a
regular basis for patients with Primary Humoral Immunodeficiency (PI).

To best serve the U.S. market and patient population, Biotest has made
significant investments in its infrastructure and its ability to efficiently
manufacture and deliver the product. In addition to a greater than $50 million
investment to enhance the capacity of its state-of-the-art Boca Raton, Florida
protein purification facility, Biotest also has developed and deployed a
comprehensive logistics operation to better serve its customers.

"The U.S. Food and Drug Administration's (FDA) approval and first commercial
sales of BIVIGAM are key corporate milestones for Biotest. The expansion and
enhancement of our manufacturing capabilities have positioned us strongly to
meet current and future patient and market demand," said Jordan Siegel, Chief
Executive Officer of BPC. "We are committed to supporting PI patients with
BIVIGAM to ensure their uncompromised living."

BIVIGAM is a sugar-free, glycine stabilized intravenous immune globulin that
was approved by the FDA December 19, 2012 and is available in 50 mL (5 grams)
and 100 mL (10 grams) tamper-evident vials. The product uses a label with an
integrated hanger and the packaging material is latex free. For Full
Prescribing Information and more information about the product, the indication
and additional services, please visit

For ordering information, please contact our customer support at
1.800.458.4244 and select Option 1.

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication. Biotest
does not intend to update the forward-looking statements and assumes no
obligation to do so.

About Biotest AG
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value
added chain that extends from preclinical and clinical development to
worldwide sales, Biotest has specialized primarily in the areas of application
of clinical immunology, hematology and intensive medicine. In its Plasma
Protein segment, Biotest develops and markets immunoglobulins, coagulation
factors and albumins based on human blood plasma. These are used for diseases
of the immune and hematopoietic systems. In the Biotherapeutic segment,
Biotest researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. Biotest has more than 1.600 employees worldwide. The preference shares
of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich,
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Dusseldorf, Frankfurt, Hamburg, Hannover,
Munchen, Stuttgart

About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation was created as a wholly-owned US
subsidiary of Biotest AG in December 2007. Innovative technologies and a sharp
focus on safety are incorporated into every facet of the business. From plasma
collection to product manufacturing and distribution – from nature for life –
Biotest Pharmaceuticals Corporation is committed to maintaining high standards
of excellence.

With further questions, please contact the Customer Support at 1-800-458-4244

SOURCE Biotest Pharmaceuticals Corporation

Contact: Dr. Monika Buttkereit, +49 (0) 6103 801-4406,, fax +49 (0) 6103 801-347
Press spacebar to pause and continue. Press esc to stop.